arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences,

FT Asia Healthcare & Life Sciences Summit

Forging Frontiers for Pharmaceuticals

Singapore |
Speakers include:
Kris Sterkens.

Kris Sterkens.

Johnson & Johnson

Xudong Yin

Xudong Yin

Novartis Greater China

Ho Weng Si

Ho Weng Si

Economic Development Board, Singapore


Thank you to everybody who joined us at the FT Asia Healthcare & Life Sciences Summit on 25 May in Singapore. We hope you enjoyed the inspiring keynotes, informative discussions and valuable networking opportunities.

fallback Add to my Calendar 05/25/2016 08:00:0005/25/2016 17:30:00trueFT Asia Healthcare & Life Sciences SummitThank you to everybody who joined us at the FT Asia Healthcare & Life Sciences Summit on 25 May in Singapore. We hope you enjoyed the inspiring keynotes, informative discussions and valuable networking opportunities.FT-Asia-Healthcare-&-Life-Sciences-Summit45ce7f1797c7b225ff7c50768075ac2dMM/DD/YYYY


Click to view

Untitled Block

“Topics are spot on in terms of the Asian pharma landscape”
- Policy and Communications Manager, Merck Sharpe & Dohme

“Very good speakers, panelists and keynotes”
- Associate Legal Director, Quintiles

“Insightful content and well-packaged”
- Corporate Communications Director, Roche Diagnostics


Follow us on Twitter:

Twitter 2


Keynote Speakers (3)

Kris Sterkens.

Kris Sterkens.

Company Group Chairman, Asia-Pacific Pharmaceuticals
Johnson & Johnson

Kris Sterkens is Company Group Chairman, Asia-Pacific Pharmaceuticals, Johnson & Johnson. The son of a physician with a passion for making a difference to the lives of others through innovation, Mr Sterkens found his calling when he joined Janssen—the pharmaceuticals division of Johnson & Johnson (J&J)—more than 25 years ago. Since being appointed Company Group Chairman of Asia-Pacific Pharmaceuticals for J&J in 2014, Mr Sterkens has secured high profile, long-term R&D investment agreements with major governments, as well as initiatives to improve access to the company’s medicines. Under his leadership, operating companies across the region have launched a range of programmes to improve the lives of patients by applying innovative technology solutions that address unmet medical needs, creating funding schemes that improve affordability and forming public-private partnerships to support people living with chronic diseases and the healthcare professionals who care for them.

Xudong Yin

Xudong Yin

Novartis Greater China

Xudong (Dong) Yin is Chairman, Novartis Greater China. He oversees the operation and development of the Novartis Group and of all its divisions (including Novartis Pharmaceuticals, Sandoz and Alcon) in China. As a member of the global Pharma Executive Committee, he reports directly to David Epstein, Head of Novartis Pharma Global.

Dr Yin joined Novartis in January 2011 from AstraZeneca China, where he served as President, AstraZeneca China and Hong Kong, and successfully led AstraZeneca China to grow into a US$1 billion business. Before AstraZeneca, Dr Yin worked at the Boston Consulting Group, focusing on pharmaceuticals industry clients in Asia. He received his bachelor’s degree in Biochemistry from Beijing University, an MBA from Harvard Business School, and a PhD in Biological Science from Stanford University.

Ho Weng Si

Ho Weng Si

Director, Biomedical Sciences
Economic Development Board, Singapore

Ho Weng Si is Director, Biomedical Sciences, with Singapore’s Economic Development Board (EDB). Since joining the EDB in 2005, Ms Ho spent three years in New York as Centre Director, before returning in 2012 to Singapore to head the Pharmaceuticals & Biotechnology industry sub-group within the Biomedical Sciences division. She earned a Bachelor’s degree in Biomedical Engineering from Columbia University and a Master’s degree in Engineering Sciences (Bioengineering) from Harvard University.

Speakers (18)

Benjamin Seet

Benjamin Seet

Executive Director, Biomedical Research Council
Agency for Science, Technology and Research, Singapore

Dr Benjamin Seet is the Executive Director of the Biomedical Research Council, Agency for Science, Technology and Research (A*STAR) in Singapore. Prior to joining A*STAR, he served as Chief of the Singapore Armed Forces Medical Corps; Chief Army Medical Officer; and Chief Medical Officer of the United Nations Department of Peacekeeping Operations in New York. Other appointments held included Visiting Consultant to Singapore’s Ministry of Health; Director, Agri-food and Veterinary Authority; Director, Health Promotion Board; and Chairman, InVivos Pte Ltd. He currently serves on the Board of the National Medical Research Council and on a number of inter-agency committees.

Dr Seet earned a Bachelor’s degree in Medicine and Surgery and a Master’s in Medicine (Ophthalmology) from the National University of Singapore, as well as a Fellowship from the Royal College of Surgeons in Edinburgh, and a Master of Public Health from Johns Hopkins University.

Deborah Elms

Deborah Elms

Executive Director
Asian Trade Centre

Deborah Elms is Executive Director of the Asian Trade Centre in Singapore. She is also a senior fellow in the Singapore Ministry of Trade and Industry’s Trade Academy. Dr Elms’ present research involves the Trans-Pacific Partnership or TPP, Regional Comprehensive Economic Partnership, ASEAN Economic Community negotiations and global value chains. Previously, she was head of the Temasek Foundation Centre for Trade & Negotiations and senior fellow of international political economy at the S. Rajaratnam School of International Studies at Nanyang Technological University. Dr Elms also has provided consulting on a range of trade issues to governments, including those of the United Arab Emirates, Sri Lanka, Cambodia, Taiwan and Singapore. She publishes the Talking Trade Blog.

Carl Firth

Carl Firth

Founder and CEO
ASLAN Pharmaceuticals

Carl Firth is Founder and Chief Executive Officer of ASLAN Pharmaceuticals. Under Mr Firth’s leadership, ASLAN has become Singapore’s first publicly listed biotech, completing an initial public offering in June 2017 with a listing on the Taipei Exchange. Previously, Mr Firth was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions. Prior to joining the banking industry, he worked for AstraZeneca for 10 years in various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China. Mr Firth was chosen as one of SCRIP’s top 10 pharmaceutical leaders alongside notable industry veterans such as Ken Frazier, CEO of Merck, and Andrew Witty, CEO of GlaxoSmithKline. Mr Firth holds a PhD from Cambridge University in Molecular Biology (Trinity College), an Executive MBA from London Business School and a degree in Molecular Biology from Cambridge University .He  is a member of Singapore’s Health and Biomedical Sciences International Advisory Council. He is also an Independent Director of Hong Kong listed Uni-Bio Sciences and Singapore’s Exploit Technologies, and is an Adjunct Professor at DukeNUS Medical School.

Claus Zieler

Claus Zieler

Senior Vice-President and Head of Commercial Operations
Bayer Pharmaceuticals Division Asia-Pacific

Claus Zieler is Senior Vice-President and Head of Commercial Operations, Bayer Pharmaceuticals Asia-Pacific. Currently based in Singapore, he has around 25 years of sales & marketing and general management experience in the pharmaceuticals industry. Previously, Mr Zieler was Head of Business Unit Cardiovascular & Neurology at Bayer Yakuhin in Japan. He began his professional career with Schering AG as a management trainee in 1991, and has since taken on roles of increasing responsibility across several regions. He has worked in various marketing and general management positions in Europe, Latin America, USA and Japan.

Mr Zieler earned a Bachelor of Arts degree in Molecular Biology from Princeton University, USA, a Master of Science in Molecular Biology from University of Wisconsin, USA, and an MBA from INSEAD, France.

Xian-Ping Lu

Xian-Ping Lu

Chipscreen Biosciences

Dr Xian-Ping Lu is CEO and CSO of Chipscreen Biosciences, a drugs discovery and development company in China focusing on innovative small molecular therapeutics. Dr Lu founded Chipscreen 15 years ago with a group of US-trained professionals. Previously, he was Director of Research at Galderma R&D (a subsidiary of L’Oreal and Nestle) in Princeton until 2000, the year he became visiting professor at China’s State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University. Dr Lu also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals.

Dr Lu has more than 20 years of biomedical research and biotech/pharmaceutical experiences in various therapeutic areas, and has published more than 80 peer-reviewed papers in prestigious journals, including Nature and Science. He is the lead inventor of more than 80 patented inventions in areas of small molecule therapeutics.

Dr Lu went to the US in 1989 for postgraduate fellowship study at the Department of Pharmacology, University of California in San Diego, followed by research at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his PhD in Molecular Biology and MS in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his BS degree in Biochemistry from Sichuan University.

Masayuki “Davey” Ishizaki

Masayuki “Davey” Ishizaki

Lead Partner, Japan
Deloitte Digital

Masayuki “Davey” Ishizaki is Lead Partner, Japan, for Deloitte Digital. He plays a leadership role at Deloitte Touche Tohmatsu for global innovation (Deloitte Consulting Innovation). Prior to joining Deloitte, Mr Ishizaki held executive leadership positions at premier consulting and technology companies in North America and Japan. He started his consulting career in Silicon Valley in the early 1990s. Mr Ishizaki’s areas of expertise include digital business innovation, global e-commerce architecture, and mobile & social strategy.

Eric A Finkelstein

Eric A Finkelstein

Professor, Health Services and Systems Research, Duke-NUS Medical School;
Executive Director, Lien Centre for Palliative Care

Eric Finkelstein is Professor of Health Services and Systems Research at the Duke-NUS Medical School, and Executive Director of the Lien Centre for Palliative Care. He also holds appointments at NUS School of Public Health and Duke University Global Health Institute. Dr Finkelstein’s research focuses on the economic causes and consequences of health behaviours, with a primary emphasis on the use of traditional and behavioural economic incentives to influence those behaviours in ways to improve the public’s health. Recent research also focuses on studies to better understand the complicated decisions around end of life care. Dr Finkelstein has published over 150 manuscripts and two books on these areas, and successfully commercialised an Obesity Cost Calculator for employers and insurers. Based on Google Scholar, he has an h-index of 46 and his publications have been cited over 13,000 times, including in the landmark US Supreme Court decision upholding the US Affordable Care Act (a.k.a. Obamacare). In 2015, Thomson Reuters selected him as one of the World's Most Influential Scientific Minds.

Richard John Saynor

Richard John Saynor

Senior Vice-President Global Head, Classic and Established Products

Richard John Saynor is Senior Vice-President Global Head, Classic and Established Products, with GlaxoSmithKline (GSK). In this role, he is responsible for driving top-line sales, leveraging the supply chain, and maximising operating profit for over £10 billion (US$14.15 billion) of post-patent products covering a number of therapy areas (Respiratory, Allergy, Anti-infectives, CNS, Dermatology and Urology). Based in Singapore, Mr Saynor oversees a large, cross-functional team comprising commercial, marketing, medical, regulatory and support functions. A seasoned pharmaceuticals professional with more than 20 years’ experience in intellectual property and generic pharmaceuticals, Mr Saynor has held senior leadership positions internationally and is well-versed in managing complex and diverse regions within the emerging markets of Latam and Asia, as well as more established markets in Europe and Canada. Prior to his current position, Mr Saynor held key regional roles for GSK’s Classic Brands business, with responsibility for post/non-patent products across the emerging markets of Asia, Latam, Africa, MENA and the CIS, as well as the EU and Japan. Before joining GSK, he held senior roles in Merck Generics and Sandoz International. Mr Saynor graduated from Bradford University with a Bachelor of Pharmacy and is a member of the Royal Pharmaceutical Society.

Yaron Turpaz

Yaron Turpaz

Chief Information Officer, Human Longevity and
Managing Director, Human Longevity Singapore

Yaron Turpaz is Chief Information Officer (CIO), Human Longevity, and Managing Director, Human Longevity Singapore. As CIO at Human Longevity, Dr Turpaz is responsible for building and growing the company’s genomic and phenotypic Knowledgebase business, and leads all bioinformatics/informatics and software engineering efforts. Dr Turpaz is expanding the informatics program at Human Longevity’s California facility, as well as building a computing and informatics program and facility in Singapore, with a focus on collaborations with the pharmaceuticals and healthcare industries. Prior to joining Human Longevity, he worked at AstraZeneca as Vice-President, R&D Information Technology; at Eli Lilly Singapore Centre for Drug Discovery as Director of Integrative Computational Sciences; and at Affymetrix as Senior Manager, Bioinformatics and Algorithms Development. Dr Turpaz has a BS in Biology from Tel Aviv University, a PhD in Bioengineering from the University of Illinois and an MBA from the University of Chicago, Booth School of Business. He has been an adjunct assistant professor at the Centre for Quantitative Medicine of Duke-National University of Singapore, Graduate Medical School, in Singapore.

Amit Backliwal

Amit Backliwal

Vice-President, Technology and Services, China and South-East Asia
IMS Health

Amit Backliwal is Vice-President, Technology and Services, for China and South-East Asia at IMS Health. Currently based in Singapore, he is at the forefront of leading the company’s agenda in healthcare across a continuum of technology-based solutions, providing strategic advice on market-entry, growth, licensing, portfolio and launch excellence. Mr Backliwal has more than 15 years’ experience, achievements and leadership in consulting, sales and general management. Prior to his current role, he was General Manager of IMS Health South Asia, where he drove business growth in India and other South Asian countries. Since joining IMS Health in 2005, his leadership roles include Head of Management Consulting and General Manager of IMS Health Thailand. Before joining IMS Health, Mr Backliwal successfully launched Battaerd Mansley, an in-clinic effectiveness and measurement business in India. He has spoken at various healthcare conferences and has presented thought-leadership pieces for several organisations, including the Indian Cancer Society. Mr Backliwal has appeared on television and print media worldwide, sharing his views on access to affordable healthcare in emerging markets. He is co-author of a report, Understanding Healthcare Access in India, and a contributor to numerous white papers. Mr Backliwal holds a Bachelor of Pharmacy degree from the University of South Australia and an MBA from the University of Adelaide, Australia.

Mark Winn

Mark Winn

Director, Diagnostics and Pharmacy
Integrated Health Information Systems

Mark Winn is Director, Diagnostics and Pharmacy, at Integrated Health Information Systems (IHiS). He is responsible for delivering healthcare solutions for Allied Health focusing on Diagnostic and Pharmacy domains. His scope covers most of the public healthcare institutions in Singapore. At IHiS, Mr Winn has been pivotal in the implementation of several key pharmacy and diagnostic projects, including the Outpatient Pharmacy Automation System implemented at many hospitals, centres and polyclinics in Singapore. The multiple-award-winning system is the region's first to combine different drug-packaging machines into one system, as well as the first to use robotic armatures from the Swiss car-manufacturing industry to achieve breakthrough speeds in filling prescriptions and cut patient waiting times by as much as 50%. The awards include the 2014 National Infocomm Award, First Runner-Up for Most Innovative Use of Infocomm Technology (Public Sector), 2015 HIMSS Elsevier Outstanding ROI Achievement Award, and 2015 SPMI Project of the Year Award, Business and Information Systems. Mr Winn has 28 years’ experience in the information technology industry, with 23 years in healthcare. Prior to joining IHiS, he led healthcare units within IBA Health, Singapore Computer Systems and National Healthcare Group.

Joyce Chang

Joyce Chang

Director, Asia-Pacific
Joint Commission International

Joyce Chang is Director, Asia-Pacific, with Joint Commission International (JCI). She is responsible for building and managing strategic relationships with Asia-Pacific healthcare organisations, ministries of health, government and international aid agencies, leading academic medical centres and hospitals, and other organisations committed to improving quality and patient safety. Prior to joining JCI, she focused on government and business financing, as well as hospital solutions within the Greater China market as a strategic account manager for Philips Medical Systems. Ms Chang also served as a consultant at The ChinaCare Group, where she concentrated on organisational restructuring, worked closely with decision-makers in the Chinese medical industry. As a management analyst at New Century International Children’s Hospital in Beijing, she managed continuous quality improvement projects and was part of the executive committee to improve profitability. Awarded Peking University’s Young Health Economist Scholarship, Ms Chang completed a research fellowship at the university’s China Center for Pharmacoeconomics & Outcomes Research. She is co-author of the World Bank Group-commissioned China Urban Service and Governance Study Health Report, an in-depth profile of China’s healthcare infrastructure. Ms Chang earned her master’s degree in health services administration and globalisation of health and her bachelor’s degree in cellular molecular biology from the University of Michigan in the US.

Samson Chiu

Samson Chiu

Director, Asia-Pacific
Pharmaceutical Security Institute

Samson Chiu is Director of the Pharmaceutical Security Institute (PSI) covering operations for the Asia-Pacific region. Prior to joining PSI, a not-for-profit membership organisation, he was deputy head of the Intellectual Property Investigation Bureau of Hong Kong Customs. Mr Chiu is highly experienced in the investigation of, and enforcement against, intellectual property crimes, in particular, counterfeit pharmaceuticals products. Working in close partnership with the pharmaceuticals industry, he launched successful projects and enforcement operations that effectively contained such pharmaceuticals problems in Hong Kong.

After joining PSI, Mr Chiu continues to contribute his experience and networks to assist the law-enforcement agencies of different countries in tackling counterfeit pharmaceuticals. Together with PSI members, including major multinational pharmaceuticals manufacturers, he has actively participated in public-awareness programmes in the region. Mr Chiu also has promoted private-public partnerships between the industry and the authorities to combat counterfeit medicines activity.

Justin Fulcher

Justin Fulcher

Founder and CEO

Justin Fulcher is Founder and CEO of RingMD. An entrepreneur focused on using technology to fundamentally change how healthcare is delivered, Mr Fulcher began programming when he was seven years old and started his first company when he was 13. Witnessing the stark lack of access to healthcare inspired him to start RingMD, a healthcare communications platform, with the mission of providing access to affordable healthcare to everyone.

Cyril Grandchamp-Desraux

Cyril Grandchamp-Desraux

Head, ASEAN Zone and Singapore Country Chair

Cyril Grandchamp-Desraux is Head, ASEAN Zone and Singapore Country Chair for Sanofi. He joined Sanofi in 2002, after starting his career as a sell-side financial analyst in Natixis. Prior to his current position at Sanofi, Mr Grandchamp-Desraux was Head of IndoChina and General Manager in Vietnam since 2012, and General Manager, Finland & Head of Diabetes Division for Nordic & Baltic countries since 2010. Earlier, he held successive positions at the company’s headquarters in Paris as Business Control & Support Manager for Global Commercial Operations, Strategic Planning for APAC Region, Attaché to the SVP of APAC Region and Chief of Staffs of the President Global Pharmaceutical Operations. Mr Grandchamp-Desraux holds a doctorate in Pharmacy with a major in Biotechnology, as well as a master’s degree in Health Economics.

Hideo Arase

Hideo Arase

Director & Senior Executive Officer, Regional Representative, India and Asia-Pacific, Terumo Corporation;
Managing Director, Terumo Asia Holdings

Hideo Arase is Director & Senior Executive Officer, Regional Representative, India and Asia-Pacific, Terumo Corporation; and Managing Director, Terumo Asia Holdings. Currently based in Singapore, Mr Arase has been working since 1977 for Terumo Corporation, a Japan-headquartered global medical technology company. Prior to his Singapore position, Mr Arase was President and CEO of Terumo Americas Holdings in the USA (2012-2015), CEO of Terumo Medical do Brasil in Brazil (2011-2012), Group President of Cardiac & Vascular Product Group in Japan (2009-2011), President & Chairman of Terumo Europe in Belgium (2006-2009), Business Manager of Interventional Systems, Terumo Europe in France (2001-2006), Manager of Terumo Europe, Interventional Systems in Belgium (1999-2001), and Branch Manager of Terumo Hong Kong Branch (1988-1991). He has wide knowledge of business development and management practices through 38 years of experience in the medical-devices

Mr Arase’s post-graduate education comprises Management Innovation at Stanford University Biodesign Executive Education (2015), Communication Strategies at New York University Leonard N. Stern Business School (2013), an Advanced Coaching Programme from Leeds Metropolitan University (2009), and an MBA from United Business Institutes in Belgium (2001). Mr Arase received the GLOBIS Alumni Award 2010 for Revolution, and is the joint author of Dangerous Syndrome of Organization, published in September 1998.

Boon Heon Tan

Boon Heon Tan

Managing Director, Southeast Asia and Korea

Boon Heon Tan is Managing Director, Southeast Asia and Korea, with UCB. He is concurrently a Venture Partner at Singapore-based IGlobe Ventures. Mr Tan joined UCB after it established a partnership in Asia in 2014 with Biogen, where he was Managing Director for Greater China, Korea and Southeast Asia. He began his career in the Singapore Economic Development Board, where he was part of a team that developed infrastructure and attracted foreign direct investments in the life sciences industry. He joined Schering-Plough in 2000, holding positions of increasing responsibility within the global marketing organisation, and subsequently was appointed head of specialty care. Following this, he relocated to China where he held different positions, including Head of Hospital Marketing, Regional General Manager and Director of Customer Solutions. After a short stint as an executive search consultant, Mr Tan joined Biogen. He holds bachelor’s and master’s degrees in Engineering (Bioengineering) from the University of Pennsylvania. Mr Tan is currently pursuing a PhD in Business at the Singapore Management University.

David  Ledger

David Ledger

VP Commercial Strategy Asia

David Ledger has over 20 years’ experience consulting to and working within the pharmaceutical/ healthcare industry. Mr Ledger joined Veeva in September 2015 as VP Commercial Strategy Asia, responsible for helping clients optimise their Veeva application investment. Prior to this, Mr Ledger was Founder and Managing Director of Vedere Group, focusing on strategic sales & marketing, CRM solutions, commercial effectiveness and performance management dashboards and reporting. After his company was acquired by IMS in January 2013, Mr Ledger headed up the IMS Health Commercial Effectiveness and Technology & Services team for ANZ/ APAC. Prior to starting his own company, Mr Ledger was Global Head of Commercial Excellence for Boehringer Ingelheim, responsible for product launch excellence, sales & marketing performance reporting & KPIs, customer segmentation & targeting initiatives and global CRM implementation.


Chair (1)

Andrew Ward

Andrew Ward

Energy Editor
Financial Times

Andrew Ward is the FT’s Energy Editor, leading global coverage of the oil and gas industry, power generation and related policy and geopolitical issues. Before taking up his current role in June 2016, Ward was Pharmaceuticals Correspondent, reporting on life sciences, medical technology and healthcare.

Prior to this, Ward was UK News Editor, leading the news desk responsible for the FT’s coverage of UK politics, policy and economics. Previously, Ward served the FT in a number of foreign reporting roles. He was the Nordic bureau chief responsible for coverage of eight countries – Sweden, Norway, Finland, Iceland, Denmark and the three Baltic states of Latvia, Estonia and Lithuania.

Ward has also been the White House correspondent, during which role he covered the George W. Bush administration and the 2008 presidential election campaign. Before moving to Washington, Ward covered business and politics in the US south-east as Atlanta Correspondent. Between 2001 and 2004, he served as Seoul Correspondent, reporting on North and South Korea.

Ward joined the FT in 1999 as a graduate trainee in London and was appointed Media Correspondent in 2000. Ward received his B.A. in Politics and Modern History from the University of Manchester, UK.

Follow Andrew Ward on twitter: @andrew_ward1

Moderator (1)

Mohit Grover

Mohit Grover

Southeast Asia Life Sciences and Health Care Industry Leader

Mohit Grover is Southeast Asia Life Sciences and Health Care Industry Leader, Deloitte, and Executive Director in the Risk Consulting practice in Southeast Asia. With 20 years of consulting experience in the Life Sciences industry, Mr Grover has in-depth expertise in enabling business growth strategies, strategic risk management and large-scale transformations in Commercial, Finance and Information Technology functions. Prior to joining Deloitte, Mr Grover held regional and global leadership positions in AstraZeneca, a global pharmaceutical company. He has led initiatives across a range of strategic topics, including innovation in commercial selling models, shared services and enterprise applications.

Agenda - 25th May

  • 8:00am
    Registration and refreshments
  • 9:00am
    FT chair’s opening remarks

    Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 9:10am
    Keynote address: Putting patients first

    The healthcare demands of populations in Asia are evolving, in part due to demographic changes and rising incomes. In response, the region’s governments are seeking to upgrade their healthcare systems. This presents business opportunities for both healthcare and drugs companies. But to make the most of these prospects, they must stay on top of the latest trends in Asia’s patient needs and expectations. Are they putting patients first?

    Kris Sterkens, Company Group Chairman, Asia-Pacific Pharmaceuticals, Johnson & Johnson

    Moderator: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 9:30am
    Dialogue: Fostering partnership and collaboration in pharma-healthcare

    In exploring different ways to foster development, pharmaceuticals (pharma) and healthcare companies worldwide are looking at collaborations that will give them an edge: smart outsourcing, for example, or academic-industry partnerships in research & development (R&D) or private-public investment. Is this the right formula?

    Claus Zieler, Senior Vice-President and Head of Commercial Operations, Bayer Pharmaceuticals Division Asia-Pacific
    Yaron Turpaz, Chief Information Officer, Human Longevity

    Moderator: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 9:50am
    Panel discussion: Exploring pharma-healthcare innovation across Asia

    For pharmaceuticals and healthcare companies, innovation is a critical tool to stay ahead of competitors and meet the shifting requirements for patient care and medicine. Medical devices are a vital element in the preventing and treating of diseases, and in the delivering of top-notch healthcare. As such, several Western multinational firms have opened R&D centres in Asia, and invested heavily in finding that breakthrough drug or that innovative medical device. But challenges and differences exist.

    • How do models of innovation differ for drugs, medical devices and healthcare companies operating in Asia?
    • Which therapeutic areas have more R&D activity in Asia than in the West?
    • Which therapeutic areas are attracting the most R&D investment?
    • Which novel methods to accelerate drugs development pipelines are being used in Asia but not elsewhere?
    • How welcoming are regulatory environments in Asia for clinical trials? Which countries are among the best and the worst?
    • What are the prospects for personalised medicine, gene therapy, epigenetics and other innovative areas?
    • What are some of the key benefits, and the most difficult challenges, of exploring innovation in Asia?

    Hideo Arase, Director & Senior Executive Officer, Regional Representative, India and Asia-Pacific, Terumo Corporation; Managing Director, Terumo Asia Holdings
    Amit Backliwal, Vice-President, Technology and Services, China and South-East Asia, IMS Health
    Carl Firth, CEO, ASLAN Pharmaceuticals
    Benjamin Seet, Executive Director, Biomedical Research Council, Agency for Science, Technology and Research, Singapore

    Moderator: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 10:45am
    Presentation: Applying health economics in Asia

    Several of Asia’s economies are among the fastest-growing in the world. Several also are among the largest markets for healthcare and pharmaceuticals. Although developing rapidly, the healthcare systems of the region’s countries are highly diverse. Only a few rigorously promote the use of health economics in policy-making for, say, drugs formulation and pricing. At the same time, they have the continuing task of improving public healthcare coverage, balancing government and private roles in the sector, and coping with the rise of non-communicable diseases such as diabetes. As Asian nations reform and upgrade healthcare and pharmaceuticals systems, how can they use health economics to make better policy decisions?

    Eric A Finkelstein, Professor, Health Services and Systems Research, Duke-NUS Medical School; Executive Director, Lien Centre for Palliative Care
    [Download PDF Presentation File]

    Moderator: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 11:05am
    Networking break
  • 11:25am
    Keynote: Focus on China—What next for its healthcare and medicines system?

    Xudong Yin, Chairman, Novartis Greater China

  • 11:35am
    Panel discussion: Focus on China—What next for its healthcare and medicines system?

    China’s government has promised its people basic healthcare for all by 2020. Towards that end, it raised annual per-capita spending on basic public health services to Rmb40 (US$6) in 2015 from Rmb35 in 2014, when total expenditure on medical and health care and family planning stood at Rmb293.12bn. China has increased support for the prevention and control of major diseases, improved provisions for medical insurance and public hospital services, and implemented significant changes to its essential medicines system. But the country’s healthcare system is fragmented and reforms have a long way to go to fully satisfy patients’ needs. What is next?

    • How will China’s economic slowdown affect its healthcare and life sciences sector?
    • As its healthcare reform continues, what more can China do to remove barriers to affordable medicine?
    • How are demand patterns and patient outcomes evolving in different therapeutic areas?
    • What are the prospects for further shifts in the government’s pricing and reimbursement policy?
    • How is China’s Essential Medicines List developing?
    • What impact are brand restrictions on drugs having on market access?
    • Can Chinese pharma firms continue to sustain R&D innovation?

    Xian-Ping Lu, CEO & CSO, Chipscreen Biosciences
    Christian Hogg, CEO, Hutchison China MediTech
    Xudong Yin, Chairman, Novartis Greater China

    Moderator: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 12:25pm
    Keynote: Sustaining pharmaceuticals operations in Asia

    Ho Weng Si, Director, Biomedical Sciences, Economic Development Board, Singapore

  • 12:35pm
    Panel discussion: Sustaining pharmaceuticals operations in Asia

    Major Western pharmaceuticals firms have set up facilities in the region not only for production but also, increasingly, for R&D. At the same time, domestic drugs companies are growing in strength; many are carving a place for themselves in the local markets and can be potential partners for global firms. For the latter, the potential to outsource certain functions, e.g. clinical trials, could mean tweaking their business models for the region. Operating in Asia carries certain risks: loss of intellectual property (IP), corruption and pricing issues, among others.

    • Where in Asia are pharma manufacturing operations still growing?
    • How are production growth rates changing across Asia?
    • What are the trends in low-cost manufacturing of medicines?
    • How is rising domestic demand changing the nature of supply chains in Asia?
    • Which regulations could negatively affect pharma manufacturing?
    • Is the increase in domestic drugs companies a boon or a bane?
    • Does having an R&D hub in Asia benefit global pharma producers?
    • How much of a threat to operations are corruption, pricing and loss of IP?
    • What are the key challenges of building a regional pharma workforce?

    Ho Weng Si, Director, Biomedical Sciences, Economic Development Board, Singapore
    Boon Heon Tan, Managing Director, Southeast Asia and Korea, UCB

    Moderator: Mohit Grover, Southeast Asia Life Sciences and Health Care Industry Leader, Deloitte

  • 1:10pm
    Networking lunch
  • 2:10pm
    Presentation: What will the TPP mean for pharma markets in Asia?

    Negotiated in 2015 between the US and 11 Pacific Rim countries, the Trans-Pacific Partnership (TPP) aims to lower trade tariffs among signatory nations, which include Japan, Singapore, Malaysia, Vietnam and Brunei. India and China are not in the club. What will be the impact of the landmark trade deal, yet to be ratified by the US Congress, on pharmaceuticals markets in Asia, in particular on the availability of cheaper medicine?

    Deborah Elms, Executive Director, Asian Trade Centre
    [Download PDF Presentation File]

    Moderator: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 2:30pm
    Dialogue: Market access for medicine—prospects and pitfalls

    Asia’s various markets present global pharmaceuticals and consumer health products firms with diverse stages of development and of unexploited potential. They also maintain differing regulatory environments, differing levels of tolerance for corruption, and differing appetites for pricing. Competition from local companies can be a challenge. As a result, no one market-access strategy will work across the region.

    • Where are the remaining frontier markets for pharma and health products in Asia?
    • What are pharma and health products firms doing to promote market access across Asia?
    • What is the potential for more price incentives for innovative medicines?
    • What is the future of price-capping?
    • How challenging is local competition for medicines and health products?
    • What dangers and opportunities accompany the growth of e-commerce?
    • What needs to be done to regulate selling of medicine over the Internet?
    • Are laws against bribery and corruption developing in line with those in the West?
    • What are the key threats to keeping pharma IP secure in Asia?

    Richard John Saynor, SVP Global Head, Classic and Established Products, GlaxoSmithKline
    Cyril Grandchamp-Desraux, Head, ASEAN Zone and Singapore Country Chair, Sanofi

    Moderator: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 3:10pm
    Networking break
  • 3:30pm
    Panel discussion: Exploring digital trends in healthcare and pharmaceuticals

    While journals, research papers and other offline materials continue to be a rich source of medical information, for physicians and consumers today following updates in healthcare and pharmaceuticals has become increasingly an online activity. But providing digital resources is just one way that the mobile, cloud, Internet of Things and similar innovations have shaken up the healthcare industry, along with the world of pharmaceuticals. Digital technologies are changing how healthcare and medicine are disseminated, how patient data are collated and analysed, how pharmaceuticals are marketed, how patient and physician relate to each other, and more. The trend is likely to continue. Are the pharmaceuticals and healthcare industries in step?

    Masayuki “Davey” Ishizaki, Lead Partner, Japan, Deloitte Digital
    Mark Winn, Director, Diagnostics and Pharmacy, Integrated Health Information Systems
    Joyce Chang, Director, Asia-Pacific, Joint Commission International
    Justin Fulcher, Founder and CEO, RingMD
    David Ledger, VP Commercial Strategy Asia, Veeva

    Moderator: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 4:30pm
    FT Interview: Fighting pharmaceuticals crime in Asia

    People in Asia are at great risk of consuming counterfeit medicine. Theft of research information, increasingly through cyber breaches, is another real threat to clinics and drugs companies. What is the cost to the industry and the public of pharmaceuticals crime? Where are the hot spots in Asia and what is being done to tackle the issue? Can regulators play a deterrent role or is the issue better handled by the sector itself? What role do agencies such as Interpol have in fighting pharmaceuticals crime?

    Samson Chiu, Director, Asia-Pacific, Pharmaceutical Security Institute

    Moderator: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 4:50pm
    Closing remarks

    Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 5:00pm
    Cocktail reception

Why Attend?

  • Hear the latest developments in healthcare reform and regulation throughout Asia
  • Learn about the market access challenges that come with expanding into Asia
  • Discuss the regional prospects for pharmaceutical research and development
  • Meet representatives from government agencies with the power to influence policy
  • Promote your organisation and develop new business relationships

Who attends?

FT Live has a reputation for delivering senior level audiences to world class thought-leadership events across the globe for nearly 40 years.

These are just some of the companies that attended FT Asia Pharma-Healthcare Summit 2015:

  • Abbvie
  • Actavis
  • Agency for Science, Technology and Research (A*STAR)
  • Asian Scientist Publishing
  • AstraZeneca
  • Baxter Healthcare
  • Bayer
  • BioSpectrum Asia
  • Boehringer Ingelheim
  • Clinuvel Pharmaceuticals
  • Eastern Health Alliance
  • EDB Singapore
  • Fresenius Medical Care Singapore
  • GE Healthcare
  • GlaxoSmithKline
  • Global Health Innovative Technology Fund
  • Hutchison China MediTech
  • ICM Pharma
  • International Finance Corporation
  • InVentiv Health
  • Janssen Pharmaceutica
  • Johnson & Johnson
  • Khoo Teck Puat Hospital
  • Lonza BioScience
  • Medicell Pharmaceutical
  • Medtronic
  • Merck Sharp & Dohme
  • Mitsubishi
  • Mundipharma
  • Novartis
  • Qiagen
  • Roche
  • Sanofi-Aventis
  • Santen Pharmaceutical
  • Schwabe Pharma Asia Pacific
  • Takeda Pharmaceuticals International GmbH
  • UCB
  • Vifor Pharma
  • Zuellig Pharma

Why Sponsor?

These are just a few of the many reasons to consider a commercial partnership with the Financial Times for the FT Asia Healthcare & Life Sciences Summit 2016:

  • Showcase your company’s solutions to a targeted and relevant audience
  • Gain direct access to senior decision makers across the healthcare supply chain
  • Benefit from brand alignment with the FT and its unrivalled credibility
  • Learn more about the specific interests and activities of your client base


12 Marina View, Asia Square Tower 2



Presented by (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

Associate Sponsors (2)

About IMS Health
Creating Connected Solutions for Better Healthcare Performance

IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. Our 7,500 services experts connect configurable SaaS applications to 10+ petabytes of complex healthcare data in the IMS One™ cloud platform, delivering unique insights into diseases, treatments, costs and outcomes. The company’s 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.

As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at

VeevaSystems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 400 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America.

Supporting Partner (1)

The Duke-NUS Medical School (Duke-NUS) was established in 2005 as a strategic collaboration between the Duke University School of Medicine, located in North Carolina, USA, and the National University of Singapore (NUS). Duke-NUS offers a graduate-entry, 4-year MD (Doctor of Medicine) training programme based on the unique Duke model of education, with one year dedicated to independent study and research projects of a basic science or clinical nature. Duke-NUS also offers MD/PhD and PhD programmes. Duke-NUS has five Signature Research Programmes: Cancer and Stem Cell Biology, Neuroscience and Behavioural Disorders, Emerging Infectious Diseases, Cardiovascular and Metabolic Disorders, and Health Services and Systems Research.

Duke-NUS and SingHealth have established a strategic partnership in academic medicine that will guide and promote the future of medicine, tapping on and combining the collective strengths of SingHealth's clinical expertise and Duke-NUS' biomedical sciences research and medical education capabilities.

For more information, please visit

Supporting Media Partners (8)

Asia Pacific Biotech News:

A Monthly Publication Covering The Latest News and Reports On Biotechnology in Asia Pacific


Asia Pacific Biotech News (APBN) is the first and only monthly magazine, offering comprehensive reports in exciting areas of pharmaceuticals, biotechnology, healthcare, nutrition and agriculture. It is a premium magazine providing industry professionals and experts with breaking news and updates on biotechnology in Asia Pacific.

Year of Establishment: 1997
Frequency: Monthly
Circulation: 4,000
Electronic Reach: 150,000 per Issue
Email Alert Subscribers: 11,000


APBN is widely read by pharmaceutical and healthcare professionals, investors, academics and researchers in both the Asia Pacific and worldwide markets.

APBN is also accessible to the large and rapidly expanding sector of professionals in biotech industries in countries such as China, Hong Kong and Taiwan. This publication also reaches out to the companies in Europe and North America that are interested in the growth of biotech companies in the Asia Pacific region.

Asian Scientist Magazine is a print and online magazine that covers breaking R&D news and feature stories from the Asian scientific and medical community. The magazine is dedicated to providing healthcare professionals, researchers, government agencies, educators and students with timely, close-to-the-scene information from Asia.

About BioSpectrum Asia

BioSpectrum is an integrated B2B media platform for the bioscience industry in the Asia Pacific region. It engages its readers from pharma, lifescience, biotech and medtech industry segments through its media products and services at a daily, fortnightly and monthly frequencies across countries, in Asia. Given its sharp reportage focus on the Asia Pacific region, it is also a one-stop information hub on Asia bioscience industry for readers from US and Europe.

fDi Intelligence is the largest FDI centre of excellence globally. Specialising in all areas relating to foreign direct investment and investment promotion, the full suite of services includes: location advertising to generate brand awareness; industry-leading intelligence tools to develop FDI strategies and identify potential investors; and tailored FDI events and investor roundtables to meet target companies and generate business leads. Products within the portfolio include fDi Markets, a database tracking crossborder greenfield investment on a real-time basis; fDi Benchmark, a database which benchmarks global locations on their attractiveness to foreign investors; and fDi Magazine.

The Voice of Pharmaceutical Manufacturing

PharmaAsia, published by Contineo Media, is the authoritative source of information for pharmaceutical manufacturers in Asia. It provides the most compelling and in-depth industry information about the latest trends and technologies of all aspects in drug manufacturing. Printed quarterly, the magazine is read by over 6,000 qualified decision-makers in the region. In addition, is a free-access website that provides daily news updates and the latest happenings in the industry complemented by specialised knowledge channels.’s detailed country-specific reports - Healthcare and Life Sciences Review - deliver up an engaging mix of insight, opinion and market intelligence straight from the corporate boardrooms of some of the world’s most high performance economies.

Download our latest country report on 





The leading global provider of thought leadership and insight dedicated to the pharma/healthcare industry the pharmaphorum channels bring together news, analysis and expert perspectives from all stakeholders in health, including commercial providers, healthcare professionals and patients. This thought-provoking content keeps the pharmaceutical industry informed and connected, driving collaboration and innovation.

About Spurwing Communications

Spurwing Communications prides itself on being a leading public and investor relations agency dedicated solely to working with healthcare sector clients.  We provide strategic counsel to corporations, Boards, senior decision makers and executives on critical communications programmes and challenges. From our Asia regional office in Singapore, Spurwing’s senior team provides cross-border comprehensive financial and corporate communications advice to some of the world’s most prominent and innovative healthcare corporations around-the-clock.

Exclusive PR Partner (1)

Bell Pottinger provides best-in-class public relations services to leading regional and multinational companies. We support clients across Asia through our regional headquarters in Singapore and our network of offices, which includes Malaysia, Hong Kong and Myanmar. Our team offers expert counsel across the spectrum of corporate and financial communications, public affairs and crisis management. We work in every industrial and commercial sector, from large-scale infrastructure projects to financial services and technology companies. We advise our clients on various opportunities and challenges, from IPO, M&A and corporate launches, to government relations and reputational issues. Our integrated approach is underpinned by a strong digital expertise and focused on delivering measurable business results.

Contact Us

Delegate Booking And Registration Enquiries
Pamela Lam
Conference Executive
Sponsorship Opportunities
Gigs Thoukidides
Senior Business Development Manager EMEA
Speaking Opportunities
Bina Jang
Senior Content Editor
Media Partner And Press Enquiries
Vian Fu
Marketing and Campaign Executive

2015 event - FT Asia Pharma-Healthcare Summit

Details of the 2015's event - FT Asia Pharma-Healthcare Summit can be found here.